EyeWorld Korea December 2023 Issue

Elevating Surgeon and Patient Satisfaction with Cataract Innovations Supplement to EyeWorld Asia-Pacific September 2022 Supplement to EyeWorld Asia-Pacific December 2023 APACRS The news magazine of the Asia-Pacific Association of Cataract & Refractive Surgeons Sponsored by Johnson & Johnson Vision TECNIS® Toric II Georgia CLEARY, MBBS, PhD, FRCOphth, Australia “When I teach and train, my priorities are patient safety, low complication rates, and surgeon safety and comfort,” Georgia Cleary MBBS, PhD, FRCOphth, FRANZCO (Australia) said as she began her presentation. Dr. Cleary’s practice received the VERITAS™ Vision System in May of this year after trialing the system in 2022, and she has received great feedback from both surgeons and trainees at the Royal Victorian Eye and Ear Hospital. Dr. Cleary walked through two surgical videos and provided her thoughts on her initial experience with the VERITAS™ Vision System. In one case, the patient had high myopia, a prior LASIK surgery, and a deep anterior chamber. The trainee surgeon worked through the case carefully, even though a significant reverse pupillary block occurred which deepened the anterior chamber. The trainee was able to lift up the iris and get the anterior chamber back into its normal configuration. “This is a case that could have gone horribly wrong with a training surgeon,” Dr. Cleary said, “but this was a nice case that I supervised with the new machine very recently out of the box.” Dr. Cleary’s initial observations thus far with the VERITAS™ Vision System is that it gives great anterior chamber stability, is adaptable with complex underwent laser-assisted in situ keratomileusis (LASIK) surgery, she will implant EDOF IOLs. A prospective study that Dr. Bissen-Miyajima conducted looked at 54 eyes of 27 patients (mean age of 66.7 years) with a bilateral implantation of the TECNIS Synergy™ IOL. Outcome measures included binocular visual acuities at various distances, defocus curve, contrast sensitivity, and patient satisfaction through a questionnaire. The results of this prospective study showed that visual acuity from 5 m to 30 cm was better than 20/25. “This is quite a promising lens,” Dr. Bissen-Miyajima remarked. The defocus curve was very smooth compared to the curve of other bifocal IOLs, and patients achieved better than 20/20 vision with a wide range of additional power. In terms of binocular contrast sensitivity at distance vision, photopic contrast sensitivities were within normal range; for binocular contrast sensitivity at intermediate and near vision, photopic contrast sensitivities were “comparable to monofocal lenses,” she said. Patient satisfaction was also at a high. One hundred percent (100%) of patients were satisfied with their near and intermediate vision while 90% of patients were satisfied with their distance vision. “Achieving 100% satisfaction for a patient receiving PC IOLs is challenging. Even with trifocal or bifocal IOLs we can achieve 90% satisfaction, but with Synergy™, all patients were satisfied,” Dr. Bissen-Miyajima said. In a separate prospective randomized comparative study by Dick et al1 that Dr. Bissen-Miyajima presented, 95 patients with bilateral implantation of Synergy™ were compared to 52 patients with bilateral implantation of PanOptix® Trifocal IOL. The study, conducted at 12 sites in Germany, Spain, Philippines, New Zealand, and Singapore, compared 3-month visual outcome measures. The results showed that a significantly higher portion of patients implanted with Synergy™ achieved ≥ 20/25 visual acuity at 33 cm. "Results from both studies showed that Synergy™ provides great visual acuity and a smooth defocus curve with high patient satisfaction. Additionally, the Synergy™ lens, compared to trifocal IOLs, provides better distance corrected near visual acuity and performs better under unfavorable conditions.” Dr. Bissen-Miyajima said. Real World Evidence with VERITAS™ Vision System and “ Achieving 100% satisfaction for a patient receiving PC IOLs is challenging. Even with trifocal or bifocal IOLs we can achieve 90% satisfaction, but with Synergy™, all patients were satisfied. ” Hiroko BISSEN-MIYAJIMA, MD Japan

RkJQdWJsaXNoZXIy Njk2NTg0